IP Library Granted Patent US 9,546,362
Granted Patent B2
US 9,546,362 · App. 14/232,465 · Granted Jan 17, 2017

Genes and proteins for alkanoyl-CoA synthesis

Inventors: Jonathan E. Page (Saskatoon, CA); Jason M. Stout (Saskatoon, CA)
Assignees: National Research Council of Canada; University of Saskatchewan
C12N9/93C12N9/00C12N9/1029C12N9/90C12N15/8243C12P7/42C12P17/06Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,546,362
App. No.
14/232,465
Granted
Jan 17, 2017
Kind
B2
Abstract

Polypeptides having alkanoyl-CoA activity have been identified and characterized, as have nucleic acids encoding these polypeptides. Expression or over-expression of the nucleic acids alters levels of cannabinoid compounds in organisms. The polypeptides may be used in vivo or in vitro to produce cannabinoid compounds.

Claims (11)

1. A process of decreasing levels of a cannabinoid compound in a cannabis plant, cannabis cell or cannabis tissue, the process comprising using a RNAi nucleic acid molecule comprising a nucleotide sequence complementary to a portion of SEQ ID NO: 1 or SEQ ID NO: 3, to silence in the cannabis plant, cannabis cell or cannabis tissue a gene that encodes an enzyme that catalyzes synthesis of an alkanoyl-CoA, in comparison to a similar variety of organism, cell or tissue grown under similar conditions but without the use of the nucleic acid molecule for silencing.

2. The process of claim 1 , wherein the cannabinoid compound is one or more of cannabigerolic acid, Δ 9 -tetrahydrocannabinolic acid, cannabidiolic acid, cannabichromenic acid, Δ 9 -tetrahydrocannabinol, cannabidiol or cannabichromene or an analog thereof comprising a side-chain of 1 to 9 carbon atoms in length.

3. The process of claim 1 , wherein the nucleotide sequence is complementary to a portion of SEQ ID NO:1.

4. The process of claim 1 , wherein the nucleotide sequence is complementary to a portion of SEQ ID NO: 3.

5. The process of claim 2 , wherein the nucleotide sequence is complementary to a portion of SEQ ID NO: 1.

6. The process of claim 2 , wherein the nucleotide sequence is complementary to a portion of SEQ ID NO: 3.

7. The process of claim 1 , wherein the use of the nucleic acid molecule comprises a method selected from RNAi, amiRNA, VIGS virus, antisense oligonucleotide, targeted mutagenesis and Targeting Induced Local Lesions IN Genomes (TILLING).

8. The process of claim 1 , wherein the enzyme is hexanoyl-CoA synthetase.

9. The process of claim 2 , wherein the enzyme is hexanoyl-CoA synthetase.

10. The process of claim 1 , wherein the alkanoyl-CoA is hexanoyl-CoA.

11. The process of claim 1 , wherein the nucleotide sequence has a length of at least 300 base pairs.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2026
From: NATIONAL RESEARCH COUNCIL OF CANADA
To: UNIVERSITY OF SASKATCHEWAN
Reel/Frame 074340/0683 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2014
From: PAGE, JONATHAN E.
To: NATIONAL RESEARCH COUNCIL OF CANADA
Reel/Frame 032751/0327 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2014
From: STOUT, JASON M.
To: UNIVERSITY OF SASKATCHEWAN
Reel/Frame 032751/0405 →
Continuity (2)
Provisional Application 61507331 · Jul 13, 2011
Related Publication 20140141476A1 · May 22, 2014